TRDAEntrada Therapeutics Inc. Common Stock
7.570USD-2.70%Mkt Cap: 294.75M $P/E: —3d ago
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considere…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap294.75M $
Enterprise Value99.57M $
Revenue (TTM)4.69M $
Gross Profit-134.36M $
Net Income (TTM)-143.75M $
Revenue/Share0.1120 USD
Last Price7.570 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees152
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.42
PEG—
EV/EBITDA-0.58
EV/Revenue21.25
P/S63.15
P/B1.01
EPS (TTM)-3.87
EPS (Forward)-3.14
52W Range
5.02022% of range16.45
52W High16.45 USD
52W Low5.020 USD
Profitability
Gross Margin0.00%
Oper. Margin-5007.02%
EBITDA Margin0.00%
Profit Margin-565.48%
ROE-46.96%
ROA-38.09%
Growth
Revenue Growth-53.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-128.51M $
CapEx (TTM)1.04M $
FCF Margin-1657.53%
FCF Yield-26.35%
Net Debt-174.46M $
Net Debt/EBITDA1.02
Balance Sheet
Debt/Equity0.17
Current Ratio10.89
Quick Ratio10.52
Book Value/Sh7.517 USD
Cash/Share6.185 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)19.00 USD
Upside (mean)+151.0%
Target Range11.00 USD – 25.00 USD
$11.00+151.0% to mean$25.00
# Analysts4
Ownership
Shares Out.38.94M
Float24.00M
Insiders12.27%
Institutions83.36%
Short Interest
Short Ratio5.0d
Short % Float8.54%
Short % Out.5.51%
Shares Short2.14M
Short (prev mo.)2.11M
Technical
SMA 506.969 (+8.6%)
SMA 2009.689 (-21.9%)
Beta-0.26
S&P 52W Chg18.16%
Avg Vol (30d)402.73K
Avg Vol (10d)268.66K
Technical Indicators
RSI (14)57.7
MACD0.1844
MACD Signal0.0826
MACD Hist.+0.1017
BB Upper8.109 USD
BB Middle6.923 USD
BB Lower5.737 USD
BB Width34.28%
ATR (14)0.4804 USD
Vol Ratio (20d)0.34x